Ventilator Waveforms & Troubleshooting | ICU Basics

This section covers the principles of ICU sedation, analgesia, and neuromuscular blockade. Sedation must always be individualized based on each patient's clinical condition and response. For patients with prolonged mechanical ventilation (beyond 48 hours), sedation should be sufficient for at least 24-48 hours in those with severe respiratory distress syndrome. Routine sedation monitoring is recommended. The approach should be based on analgesia first, then sedation. Fentanyl is preferred for initial analgesia due to rapid onset (less than 1 minute) and short duration (2-4 hours). Presentation: 100mcg/12ml or 500mcg/10ml ampoules. Standard preparation is 2000mcg in 100cc (20 mcg/cc). Bolus doses should be given through infusion pumps with bolus function or using secondary syringes to prevent overdose. Fentanyl accumulation occurs in hepatic failure and obese patients, prolonging awakening times. Propofol is preferred for sedation due to rapid onset (3 minutes to maximum effect) and short duration (3-8 minutes), allowing quick patient awakening. Presentation: 10% (20ml), 1% (100ml), and 2% (20ml). Initial dosing is typically 1 mg/kg/hour for 1% concentration. Important considerations include propofol infusion syndrome (with doses below 3 mg/kg/hour being safer), hypertriglyceridemia, and the need for adequate ventilatory support due to respiratory depression risk. Neuromuscular blockers have four main indications: orotracheal intubation, severe respiratory distress (PaO2 <150 mmHg), abdominal hypertension, and hypothermia. The primary concern is ensuring deep sedation to prevent patient awareness and potential complications. Key adverse effects include delayed awakening, anaphylaxis, and malignant hyperthermia. They should not be used for initial synchrony management but rather as secondary therapy after optimizing sedation and analgesia. Rocuronium is preferred for rapid sequence intubation due to brief onset (1.2 mg/kg for 70kg patient). For continuous infusion, rocuronium is preferred over atracurium because it does not accumulate and elimination is independent of hepatic and renal function. Initial infusion dose is 0.6 mg/kg/hour.

Neuromuscular blockade is indicated when ARDS patients fail to respond to initial treatments and have PF ratio less than 150. Paralysis prevents patient-ventilator dyssynchrony and protects against self-inflicted lung injury from patient's own breathing efforts. Patients must receive concurrent sedation and analgesia to prevent awareness and discomfort. This intervention is part of a stepwise escalation approach for severe ARDS and has been shown to reduce mortality when combined with other supportive measures.

Sedation in critical care equals sedoanalgesia (sedation plus analgesia). Patients under mechanical ventilation always need adequate analgesia but not necessarily deep sedation. Three patient groups require deep sedation: (1) Respiratory patients with severe ARDS (PaFiO2 <150) or severe airway trapping (COPD/asthma exacerbation), (2) Neurocritical patients with suspected elevated intracranial pressure (neurotrauma, stroke, refractory status epilepticus), and (3) Patients with unstable thoracic trauma or abdominal compartment syndrome until resolved. Assessment scales include RASS (+4 to -5, target 0 for most patients, -4 to -5 for deep sedation) and Ramsay (1-6, target 2-3). Continuous infusion is preferred over bolus. Sedative agents include propofol (1-3 mg/kg/hour, immediate onset, no analgesia, ideal for neurocritical patients), ketamine (dissociative anesthetic with analgesia, cardio-stable, bronchodilatory), dexmedetomidine (alpha-2 agonist, slower onset, causes hypotension/bradycardia), and midazolam (avoid when possible due to accumulation and prolonged ventilation). Acetaminophen is first-line analgesia. Preferred opioids include fentanyl (0.5-3 mcg/kg/hour), remifentanil (ultra-short-acting), tramadol, and buprenorphine. After 5-7 days of continuous opioid infusion, doses should be reduced by 50% to prevent opioid-induced hyperalgesia and withdrawal syndrome.

Three major drug families are used in airway management: (1) Opioids (fentanyl 2-5 mcg/kg) for analgesia, (2) Inductors/hipnotics (midazolam, etomidate, ketamine, propofol) for sedation, and (3) Neuromuscular blockers (succinylcholine, rocuronium) for rapid sequence intubation. Ketamine has advantages including shorter onset, longer duration, and catecholamine release causing tachycardia/hypertension. Propofol should be avoided in hypovolemic or unstable patients. A survey revealed 63% of physicians lack access to all necessary drugs, with fentanyl being most commonly unavailable.

This section establishes spontaneous breathing trials as the gold standard for weaning assessment. Research demonstrates that 75% of patients require no gradual weaning and can be extubated directly after successful trial. Clinical practice should involve aggressive trial implementation even on seemingly unstable patients, as many surprise clinicians with their capabilities. Recommended protocol includes once-daily trials for awake, alert, oriented patients with adequate airway control. Trial duration varies: 30 minutes for patients on ventilation less than 72 hours, up to 1-2 hours for longer-term patients. Success criteria include no significant increase in work of breathing during the trial period.

This section covers the spontaneous breathing trial (SBT) protocol and extubation criteria. Pre-weaning preparation includes stopping sedation (1-2 hours due to drug accumulation), stopping intravenous fluids to reduce aspiration risk, positioning the patient semi-recumbent, and preparing equipment (suction, endotracheal tube, face mask, oxygen). The SBT involves reducing ventilator settings (inspiratory pressure to 10 cm H2O, PEEP to 5 cm H2O) and monitoring the patient's response. The trial should last 30 minutes minimum and 2 hours maximum. Extubation failure is indicated by: agitation, respiratory distress, oxygen saturation below 90%, respiratory rate increase of more than 20% above baseline, heart rate increase of more than 20% above baseline, or heart rate exceeding 120-140 bpm.

This section covers the systematic approach to weaning patients from mechanical ventilation. Weaning goals include PaO2 55-80 mmHg. The process begins by reducing FiO2 below 60% (to prevent oxygen toxicity) followed by gradual PEEP reduction. Daily spontaneous breathing trials (30 minutes on pressure support) assess tolerance. Prolong to 1 hour if concerned about failure. T-piece trials increase difficulty for COPD/heart failure patients. The Rapid Shallow Breathing Index (RSBI = RR/Tidal Volume) >105 predicts extubation failure. Cuff leak testing (audible leak and tidal volume decrease >100ml) confirms no tracheal swelling. Negative inspiratory force < -25 cm H2O indicates adequate diaphragm strength. Patients must follow commands before extubation. Aggressive extubation is encouraged, accepting occasional reintubations as appropriate.

Pressure support ventilation is a patient-triggered, pressure-limited breath where the patient has influence on respiratory rate, inspiratory time, and tidal volume. It is typically a weaning mode where pressure support is slowly decreased until the patient is ready for extubation. Every breath is patient-triggered (negative deflection in pressure-time waveform), inspiratory time is variable, and it is a flow-cycled mode that cycles off when flow decreases to a preset percentage of peak inspiratory flow. Advanced modes include Airway Pressure Release Ventilation (APRV), an open lung, pressure control, inverse ratio mode that promotes oxygenation by allowing recruitment over a longer period with higher mean airway pressure but lower peak airway pressure. APRV components include P-high (25-30 cm H2O), P-low (0-5 cm H2O), T-high (4-6 seconds), and T-low (short to prevent pressure from reaching zero). Proportional Assist Ventilation (PAV) delivers support proportional to patient effort, calculating respiratory mechanics using the equation of motion by applying a short end-inspiratory pause every 4-10 breaths.

This section covers three key advanced ventilation modes. APRV (Airway Pressure Release Ventilation) delivers two constant pressures (P_high and P_low) with long inspiratory phases (4-6 sec) to improve alveolar recruitment, reduce sedation, and allow spontaneous breathing. It is used for ARDS, acute lung injury, and atelectasis but contraindicated in COPD. PAV (Proportional Assist Ventilation) measures lung compliance and resistance breath-by-breath to deliver variable pressure support matching patient effort, improving synchrony and benefiting COPD patients. NAVA (Neurally Adjusted Ventilatory Assist) detects diaphragm electrical activity to trigger breaths, improving synchrony for patients with triggering problems. Each mode addresses specific clinical challenges in mechanical ventilation management.

Proportional Assist Ventilation (PAV) is an advanced pressure-controlled mechanical ventilation mode that dynamically adjusts pressure support based on the patient's spontaneous breathing efforts, using algorithms and feedback mechanisms like P0.1 measurements to provide more assistance when the patient works harder and less when breathing is easier; unlike volume control which reduces support with decreased patient effort, PAV creates a positive feedback system where increased patient work of breathing triggers increased ventilator support, making it particularly suitable for patients with abnormal respiratory mechanics (resistance or compliance issues) who still have intact spontaneous breathing drive.

APRV is a pressure control mode characterized by prolonged high-pressure periods separated by brief pressure releases. It uses four primary settings: P_high (high pressure), P_low (low pressure, typically zero), T_high (time at high pressure), and T_low (time at low pressure, usually 0.5 seconds). The ventilator holds high pressure for T_high, then rapidly releases to P_low for T_low before returning to high pressure. Despite P_low being set to zero, auto-PEEP prevents true zero pressure due to the short release time. APRV maintains high mean airway pressure to recruit and keep alveoli open for improved oxygenation, particularly beneficial in ARDS patients. Spontaneous breathing is permitted during the high-pressure phase, though patients often require additional CO2 removal support.

APRV is a patient-friendly mode using high levels of continuous positive airway pressure with periodic release breaths. Four key variables are set: PEEP high (15-20 cm H2O), PEEP low (typically 0 cm H2O), time at PEEP high (5-6 seconds), and release breath duration (less than 1 second). The concept is to keep alveoli open throughout the respiratory cycle while allowing CO2 elimination during release breaths. Patients can take spontaneous breaths throughout the cycle, and some ventilators allow adding pressure support to release breaths.